3654 results for «600»
3654 results
Monotherapy vs. DAPT: striking the balance between ischemia and bleeding
20 May 2026 – From EuroPCR 2026
This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral...
Complex anatomy in STEMI patients
19 May 2026 – From EuroPCR 2026
This session addresses the unique challenges posed by complex coronary anatomy in STEMI patients. Through detailed case discussions, it highlights management of anomalous culprit origins, multifaceted infarcts, rare presentations, and urgent primary PCI strategies in anatomically complex scenarios. The session emphasizes adaptive techniques to navigate unexpected...
When a primary PCI goes wrong
19 May 2026 – From EuroPCR 2026
This session investigates complications encountered during primary percutaneous coronary interventions (PCI). It covers management of no-reflow phenomena, innovative guide extension catheter aspiration techniques for thrombus-rich STEMI, challenges when balloon crossing fails, vein graft PCI pitfalls, and complex concurrent ischemic events involving myocardial infarction and limb ischemia....
Regulatory and reimbursement pathways for MedTech innovators
19 May 2026 – From EuroPCR 2026
This session provides an in-depth exploration of regulatory and reimbursement pathways critical for MedTech innovators. It covers the transition challenges from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR), sharing lessons learned and success stories. The session also addresses reimbursement frameworks in the...
The thin line between success and failure in MedTech start ups - Lessons learnt
18 May 2026 – From EuroPCR 2026
This session examines critical success factors for MedTech start-ups through real-world examples, discussing challenges, investment dynamics, and the pivotal role of the Chief Medical Officer and investor syndicates in fostering sustainable growth.
Strategical approaches to treat patients with multivessel disease
20 May 2026 – From EuroPCR 2026
This comprehensive session focuses on strategic approaches to manage patients with multivessel coronary artery disease. It covers a spectrum of topics including ostial stent implantation techniques, the impact of center volume on CT-guided angiography post-CABG, and physiology-guided PCI versus angiography alone. Insights into percutaneous revascularisation strategies...
CTO PCI in images and case examples: what is new in 2026?
07 Jul 2026
Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
From PROTECT-AF to CHAMPION-AF: Where do we stand today?
01 Jul 2026
In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.
Author
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
